ICON and ACRONET Sign Alliance Agreement in Japan
ICON
and
ACRONET
announced they have signed an alliance agreement. Through the agreement, ICON and ACRONET will collaborate to offer global and Japanese pharmaceutical clients a full range of clinical development capabilities to manage trials on a regional or global basis.
With headquarters in Tokyo and additional offices in Osaka, Fukuoka, and New York, ACRONET employs around 500 clinical development professionals. ICON has been operational in Japan since 1995 and offers a wide range of clinical development services and contract staffing from its offices in Tokyo and Osaka.
Commenting on the alliance, Alan Morgan, ICON’s Group President, Clinical Research Services, said, “Japan is an important center for clinical research and ICON has a well established presence there. Recent changes in the regulatory landscape mean that an increasing number of Japanese based pharmaceutical companies are looking to run development projects on both a domestic and pan regional basis. The alliance between ICON and ACRONET will benefit clients, who can be assured of a wider range of quality drug development services alongside truly global expertise.”
Shogo Nakamori, ACRONET’s President & CEO, said, “The number of global clinical trials involving the triad regions of US, EU and Japan has increased gradually in recent years and this trend will continue to accelerate. This is one of the challenging areas for the Japanese pharmaceutical industry and ACRONET is now ready to contribute and support the above challenging areas through this alliance with ICON.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
